计算机模拟、细胞与果蝇模型鉴定新型KCNT1癫痫药物
该研究针对KCNT1功能获得性突变所致耐药性癫痫,利用KCNT1通道结构进行计算机模拟筛选已知药物库,预测可阻断通道孔的药物。细胞电生理显示8种药物中4种显著降低患者特异性突变通道的钾电流,果蝇模型进一步验证2种药物减少癫痫表型,其中antrafenine可透过小鼠血脑屏障。研究提示antrafenine有望成为KCNT1癫痫的新治疗选择。
要点
- 计算机模拟筛选结合细胞电生理和果蝇模型可有效发现KCNT1通道抑制剂。
- 8种已知药物中4种显著降低患者突变KCNT1通道钾电流,2种在果蝇中减少癫痫表型。
- antrafenine可透过小鼠血脑屏障,具备治疗KCNT1癫痫的转化潜力。
核心结论
- antrafenine可降低KCNT1通道活性、减少果蝇癫痫活动并透过小鼠血脑屏障,提示其作为KCNT1癫痫新治疗的可能。
研究设计与样本
- 基于KCNT1通道结构对已知药物库进行计算机模拟筛选,预测可阻断通道孔的候选药物。
- 利用电生理分析细胞KCNT1通道抑制,采用果蝇bang-sensitive实验分析癫痫抑制,并用液相色谱-质谱法分析一种药物在小鼠的脑穿透性。
主要发现
- 8种已知药物在体外针对患者特异性突变KCNT1通道进行检测,其中4种显著降低K+电流幅度。
- 4种药物进一步在体内人源化果蝇KCNT1癫痫模型中分析,2种减少癫痫表型。
- antrafenine在小鼠中显示可透过血脑屏障。
临床怎么用
- antrafenine可作为KCNT1相关癫痫的候选药物进一步临床前和临床开发。
- 计算机模拟、体外和体内序贯筛选策略可推广至其他已明确疾病机制的人类疾病药物发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Hyperactive KCNT1 potassium channels, caused by gain-of-function mutations, are associated with a range of epilepsy disorders. Patients typically experience drug-resistant seizures and, in cases with infantile onset, developmental regression can follow. KCNT1-related disorders include epilepsy of infancy with migrating focal seizures and sleep-related hypermotor epilepsy. There are currently no effective treatments for KCNT1 epilepsies, but suppressing overactive channels poses a potential strategy. METHODS: Using the KCNT1 channel structure we in silico screened a library of known drugs for those predicted to block the channel pore to inhibit channel activity. Cellular KCNT1 channel inhibition was analyzed using electrophysiology and Drosophila bang-sensitive assays were used to analyze seizure suppression. Brain penetration of one drug was analyzed using liquid chromatography-mass spectrometry in a mouse. RESULTS: Eight known drugs were investigated in vitro for their effects on patient-specific mutant KCNT1 channels, with 4 drugs showing significant reduction of K+ current amplitudes. The action of the 4 drugs was then analyzed in vivo and 2 were found to reduce the seizure phenotype in humanized Drosophila KCNT1 epilepsy models. One drug, antrafenine, was shown to cross the blood-brain barrier in mice. INTERPRETATION: This study identified a known drug, antrafenine, that reduces KCNT1 channel activity, reduces seizure activity in Drosophila, and crosses the blood-brain barrier in the mouse, suggesting its potential applicability as a new treatment for KCNT1 epilepsy. The sequential in silico, in vitro, and in vivo mechanism-based drug selection strategy used here may have broader application for other human disorders where a disease mechanism has been identified. ANN NEUROL 2025;98:1261-1274.
引用
- Ricos MG, Cole BA, Hussain R, et al. Identification of New KCNT1-Epilepsy Drugs by In Silico, Cell, and Drosophila Modeling. Ann Neurol. 2025. PMID: 40944494. doi:10.1002/ana.78031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。